Inclusion Criteria:

- Histologically confirmed diagnosis of malignant melanoma.

- Previously untreated and non-resectable disease

- Measurable or evaluable tumour.

- Age ≥ 18 and ≤ 75 years.

- Performance status ECOG-WHO 0, 1 and 2 (Appendix III)

- Written informed consent (Appendix II)

- Adequate bone marrow liver, heart and renal function:

- WBC count >3.0 x 109/L and platelets count >100 x 109/L.

- ASAT, ALAT <2 x upper normal laboratory value.

- Serum creatinine <2 x upper normal laboratory value.

Exclusion Criteria:

- Previous treatment with chemotherapy.

- Clinical signs of brain metastases.

- Severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable
cardiac or coronary artery disease.

- Severe active infections such as HIV or hepatitis B or Hepatitis C.

- Medication for severe intercurrent disease which might affect immunocompetence (e.g.
immunosuppressants, systemic corticosteroids).

- Pregnancy, breast-feeding or absence of adequate contraception for fertile patients.

- Simultaneously participation in other clinical studies.

- Any reason why, in the opinion of the investigator, the patient should not
participate.